Sanofi and Denali Therapeutics
Nov 06, 2018
FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan
FDA approves Zulresso of Sage Sage Therapeutics, a clinical-stage biopharmaceutical company committed to the treatment of central nervous system (CNS) disorders, receives U.S. approval for its postpartum depression (PPD) drug Zulresso from the Food and Drug Administration when received 17-1 in favour of the therapy...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
